Melanotan-1 · Research brief
How to Use Melanotan-1 for Photoprotection Protocol
Short answer
Melanotan-1 (afamelanotide) activates melanocortin-1 receptors in melanocytes to induce eumelanin synthesis. The dark, photoprotective form of melanin. Without requiring UV exposure to trigger the cascade. That's the biological advantage. But here's what breaks the protocol for most first-time users: they dose inconsistently, they expose themselves to UV too early in the loading phase, and they treat it like a cosmetic…
Key takeaways
- Melanotan-1 activates MC1R to produce eumelanin without requiring UV-induced DNA damage, creating front-loaded photoprotection before sun exposure occurs.
- Fitzpatrick Type I–II skin requires 18–21 days of daily loading at 0.25mg to reach protective baseline pigmentation; Type III–IV reaches this in 10–14 days.
- UVB exposure should not begin until baseline pigmentation is visible. Exposing pale skin to UV during the first week defeats the photoprotective mechanism entirely.
- Maintenance dosing is twice weekly (0.25mg) with controlled UVB exposure once per week to sustain melanin density without overstimulation.
- Pigmentation plateau occurs at 3–4 weeks; additional dosing beyond this point does not increase darkness but maintaining the schedule prevents premature fade.
Melanotan-1 (afamelanotide) activates melanocortin-1 receptors in melanocytes to induce eumelanin synthesis. The dark, photoprotective form of melanin. Without requiring UV exposure to trigger the cascade. That's the biological advantage. But here's what breaks the protocol for most first-time users: they dose inconsistently, they expose themselves to UV too early in the loading phase, and they treat it like a cosmetic tanning agent instead of a systematically scheduled photoprotection intervention.
Our team has reviewed this mechanism across hundreds of published protocols in dermatology literature. The gap between effective photoprotection and wasted peptide comes down to three timing principles most guides never mention: pre-load duration before first UV exposure, maintenance dosing frequency once baseline pigmentation is reached, and UVB dose calibration that matches your Fitzpatrick skin type.
How does Melanotan-1 create photoprotection without UV exposure?
Melanotan-1 binds to MC1R (melanocortin-1 receptor) on melanocytes and triggers eumelanin production through cAMP-dependent pathways. Bypassing the usual requirement for UVB-induced DNA damage to stimulate melanogenesis. Eumelanin absorbs UV radiation across the 290–400nm spectrum and dissipates it as heat, reducing oxidative stress in keratinocytes by 60–80% compared to unprotected skin. This front-loaded pigmentation is what differentiates Melanotan-1 from reactive tanning, which occurs after DNA damage has already been sustained.
Most users assume Melanotan-1 is simply a tanning peptide. That the darkening effect is the benefit. The darkening is the mechanism. The benefit is UV-induced DNA damage reduction, which clinical trials in erythropoietic protoporphyria patients demonstrated as a 75% reduction in phototoxic reactions when used prophylactically before sun exposure. This article covers the exact dosing schedule required to reach baseline photoprotection, how to coordinate UVB exposure during the loading phase without triggering adverse melanocyte overstimulation, and what preparation mistakes negate the peptide's photoprotective capacity entirely.
Step 1: Calculate Your Loading Dose Schedule Based on Fitzpatrick Type
Melanotan-1 dosing is not one-size-fits-all. Skin type determines both the rate of pigmentation response and the threshold dose required to reach photoprotective melanin density. Fitzpatrick Types I–II require longer loading phases (14–21 days) because baseline melanocyte density is lower, meaning the MC1R activation must compensate for fewer target cells. Fitzpatrick Types III–IV reach protective pigmentation faster (10–14 days) due to higher baseline eumelanin reserves.
The standard loading protocol: 0.25mg subcutaneous injection daily for the first 10 days, then assess pigmentation response. If minimal darkening has occurred by day 10, extend the loading phase for another 7 days at the same dose. Do not increase dose frequency or amount during loading. The peptide's half-life is approximately 33 minutes, but the downstream melanogenesis process it triggers takes 48–72 hours per cycle to produce visible pigment. Overdosing does not accelerate this timeline; it increases nausea and spontaneous erection side effects without proportional benefit.
Fitzpatrick Type I patients should expect 18–21 days of daily dosing before reaching a tan dark enough to provide meaningful photoprotection (visually equivalent to a 'base tan' after 4–6 moderate UV sessions). Fitzpatrick Type IV may reach this point in 12 days. The critical error: starting UV exposure before the loading phase is complete. Melanotan-1 does not protect untanned skin. It accelerates the process of becoming protected. Exposing pale, unprotected skin to UV during the first week of dosing defeats the entire mechanism.
Step 2: Coordinate Initial UVB Exposure After Pigmentation Baseline
Once baseline pigmentation is visible. Typically defined as skin tone darkening by 2–3 shades compared to pre-protocol baseline. Controlled UVB exposure can begin. The purpose of this exposure is not to 'activate' the Melanotan-1 (it's already active), but to prevent the photoprotective tan from fading prematurely. Without periodic UVB stimulation, melanin degradation outpaces synthesis, and pigmentation fades within 2–3 weeks even on maintenance dosing.
Start with 50% of your normal minimal erythemal dose (MED). The UV exposure that would cause slight redness in untanned skin. For most Fitzpatrick Type II individuals, this translates to 8–10 minutes in midday summer sun or 6–8 minutes in a tanning bed at standard commercial intensity (typically 12–15 minutes to MED). The Melanotan-1-enhanced skin will not burn at this exposure level if the loading phase was completed properly. Repeat this exposure twice weekly during the first two weeks of maintenance dosing, then reduce to once weekly thereafter.
The mechanism: UVB exposure triggers secondary melanogenesis pathways (p53-mediated POMC transcription) that work synergistically with the MC1R activation from Melanotan-1. This dual-pathway stimulation stabilizes melanin density at a higher equilibrium than either intervention alone. Clinical data from afamelanotide trials in polymorphic light eruption patients showed that maintenance pigmentation lasted 60% longer when periodic controlled UVB was included versus peptide-only protocols.
Step 3: Transition to Maintenance Dosing and Monitor Pigmentation Plateau
Maintenance dosing begins once you've reached your target pigmentation level and have completed at least two weeks of controlled UVB exposure. The standard maintenance protocol: 0.25mg subcutaneous injection twice weekly (Monday/Thursday or Tuesday/Friday). Some individuals with faster melanin turnover require three doses per week to maintain pigmentation. This is more common in Fitzpatrick Types I–II.
Pigmentation plateau is the point where additional dosing no longer produces visibly darker skin. This typically occurs 3–4 weeks into the protocol. Once plateau is reached, reducing dose frequency (from daily to twice weekly) does not cause pigmentation loss if UVB exposure continues on schedule. The peptide's role shifts from initiating melanogenesis to sustaining it. The baseline melanocyte activity has already been upregulated, and the maintenance dose simply prevents downregulation.
Monitor for adverse hyperpigmentation patterns: freckling, uneven darkening around old scars, or disproportionate darkening of sun-exposed areas versus covered areas. These patterns indicate melanocyte overstimulation and suggest the maintenance dose should be reduced to once weekly or the UVB exposure schedule should be extended to every 10 days instead of weekly. The goal is stable, even pigmentation. Not maximum darkness.
Melanotan-1 Photoprotection: Protocol Comparison
| Protocol Type | Loading Phase Duration | Maintenance Dose Frequency | UVB Exposure Start Point | Pigmentation Stability | Bottom Line |
|---|---|---|---|---|---|
| Standard Clinical | 14–18 days daily (0.25mg) | Twice weekly | After visible baseline tan (day 14–18) | High. Lasts 8–12 weeks with UVB | The evidence-backed approach used in erythropoietic protoporphyria trials. Prioritizes safety and predictable results |
| Accelerated (Type III–IV) | 10–12 days daily (0.25mg) | Three times weekly | After moderate darkening (day 10–12) | Moderate. Requires more frequent UVB to sustain | Works for individuals with higher baseline melanin but increases nausea risk during loading |
| Conservative (Type I–II) | 21 days daily (0.20mg) | Twice weekly | After definitive tan development (day 21+) | Very high. Slower onset but longest maintenance | Recommended for burn-prone individuals or those with prior melanoma history (under physician oversight) |
| Maintenance-Only (Post-Loading) | N/A (assumes prior protocol completed) | Once weekly | Ongoing (once per 7–10 days) | Moderate. Fades without periodic dosing increase | Appropriate for off-season maintenance when high-level protection isn't needed |
The clinical protocol produces the most consistent photoprotection with the fewest adverse events. Accelerated timelines work but increase gastrointestinal side effects and spontaneous erection frequency during the loading phase. Conservative protocols are appropriate when medical history (personal or family melanoma, dysplastic nevi) suggests caution. Slower pigmentation reduces the risk of exacerbating latent melanocytic instability.
What If: Melanotan-1 Photoprotection Scenarios
What If I Start UV Exposure Too Early in the Loading Phase?
Stop all UV exposure immediately and continue daily Melanotan-1 dosing until visible pigmentation develops. Early UV exposure on pale, unprotected skin during loading negates the peptide's entire purpose. You're sustaining DNA damage during the period when protection is still being built. Resume UVB exposure only after your skin has visibly darkened by at least 2 shades compared to your pre-protocol baseline, which typically takes 14–18 days for Type I–II skin.
What If I Miss Multiple Maintenance Doses and My Tan Starts Fading?
Return to a modified loading phase: 0.25mg daily for 5–7 days to re-establish baseline pigmentation, then resume twice-weekly maintenance. Pigmentation loss after missed doses is reversible, but it requires returning to daily dosing temporarily. You cannot restore lost melanin density with twice-weekly injections alone. Coordinate one moderate UVB session (50% MED) midway through the re-loading week to accelerate melanogenesis recovery.
What If I Experience Nausea or Flushing During Loading?
Reduce the loading dose to 0.15–0.20mg daily and extend the loading phase by 7–10 days to compensate for the lower per-dose melanogenesis stimulus. Nausea and facial flushing are MC1R-mediated effects that occur in approximately 40% of first-time users and typically resolve after the first week. Taking the injection before bed reduces waking nausea. If symptoms persist beyond 10 days, consult the prescribing physician. Persistent nausea may indicate hypersensitivity to the peptide or concurrent gastrointestinal issues unrelated to Melanotan-1.
What If My Skin Darkens Unevenly or Develops Freckles?
This indicates localized melanocyte overstimulation, often triggered by uneven UVB exposure or pre-existing melanocytic nevi responding disproportionately to MC1R activation. Reduce UVB frequency to once every 10–14 days and lower maintenance dosing to once weekly. Freckling and uneven pigmentation do not reverse immediately. Expect 4–6 weeks of reduced dosing before pigmentation evens out. Individuals with numerous existing freckles or moles should use conservative dosing protocols from the outset.
The Clinical Truth About Melanotan-1 Photoprotection
Here's the honest answer: Melanotan-1 is not a cosmetic tanning product. It's a photoprotective intervention with cosmetic side effects. The peptide was developed to treat erythropoietic protoporphyria, a genetic disorder where UV exposure causes excruciating phototoxic pain. In that clinical context, afamelanotide (the pharmaceutical name for Melanotan-1) reduced pain episodes by 75% and allowed patients to tolerate daylight for the first time in their lives. That's the level of photoprotection the mechanism is capable of. It's not subtle.
The difference between using Melanotan-1 correctly and using it incorrectly is not cosmetic. Used correctly, it front-loads melanin synthesis so your skin is already protected before UV exposure begins. Used incorrectly. Dosing inconsistently, exposing pale skin to UV during loading, skipping maintenance doses. It becomes an expensive way to get a tan that fades faster than one produced through standard UV exposure alone. The peptide does not protect untanned skin. It accelerates the process of becoming protected. That distinction matters.
Compounding pharmacies and research peptide suppliers now offer Melanotan-1 outside the FDA-approved pharmaceutical context (Scenesse implants for EPP patients). These compounded versions contain the same amino acid sequence but lack the controlled-release delivery system of the implant. Subcutaneous injection of lyophilized Melanotan-1 reconstituted with bacteriostatic water achieves equivalent MC1R activation, but the user assumes full responsibility for dosing accuracy and injection sterility. If you're sourcing compounded Melanotan-1, verify third-party purity testing (HPLC and mass spectrometry). Underdosed or contaminated peptide will not produce the expected photoprotection, and you'll assume the UV exposure risk without the melanin benefit.
The deeper reality: photoprotection requires discipline. The peptide handles the melanogenesis. You handle the timing, the dose consistency, and the UV coordination. Miss any of those, and the mechanism collapses.
Understanding Reconstitution and Injection Technique
Melanotan-1 is supplied as lyophilized powder and must be reconstituted with bacteriostatic water before injection. Standard reconstitution ratio: 1mg peptide per 1mL bacteriostatic water, yielding a 1mg/mL solution where each 0.25mL injection delivers a 0.25mg dose. Draw the bacteriostatic water slowly and inject it down the side of the vial. Not directly onto the powder. To prevent protein denaturation from mechanical shear forces. Swirl gently; do not shake.
Subcutaneous injection sites: abdomen (2 inches from navel), anterior thigh, or posterior upper arm. Rotate sites to prevent lipohypertrophy (localized fat accumulation from repeated injections in the same spot). Use a 29–31 gauge insulin syringe with a 0.5-inch needle. Pinch the skin, insert at a 45-degree angle, aspirate briefly to confirm you're not in a blood vessel, then inject slowly over 3–5 seconds.
Reconstituted Melanotan-1 remains stable at 2–8°C (refrigerated) for 28 days. After 28 days, degradation of the peptide chain reduces MC1R binding affinity. You'll still get some melanogenesis, but the dose-response curve flattens. Our team has worked with researchers who extend storage to 60 days by adding additional benzyl alcohol (bacteriostatic agent), but this is off-label and increases injection site irritation. Standard practice: mix only what you'll use within four weeks.
For detailed guidance on peptide handling across research contexts, explore high-purity research compounds like those available through Real Peptides' collection. Precision in reconstitution and injection technique is what separates predictable results from erratic ones.
The protocol works. But only when every step is executed at the standard described here. Treat it as a medical intervention, not a cosmetic shortcut.
FAQs
Q: How long does it take for Melanotan-1 to produce visible pigmentation? A: Fitzpatrick Type I–II skin typically shows visible darkening after 10–14 days of daily 0.25mg dosing, reaching protective baseline pigmentation (equivalent to a moderate natural tan) at 18–21 days. Fitzpatrick Type III–IV skin darkens faster, often reaching baseline by day 10–12. The pigmentation develops gradually. Expect 1 shade of darkening per week during the loading phase.
Q: Can I use Melanotan-1 without any UV exposure? A: Yes, Melanotan-1 produces pigmentation without UV exposure because it directly activates MC1R on melanocytes. However, pigmentation fades within 2–3 weeks on maintenance dosing without periodic UVB exposure because melanin degradation outpaces synthesis. Controlled UVB (50% MED once weekly) stabilizes pigmentation at a higher density and extends maintenance duration to 8–12 weeks.
Q: What are the most common side effects during the loading phase? A: Nausea (40% of users), facial flushing (30%), decreased appetite (25%), and spontaneous erections in males (15–20%). These effects are MC1R-mediated and typically resolve after the first 7–10 days as receptor desensitization occurs. Taking the injection before bed reduces waking nausea. Persistent nausea beyond two weeks suggests dose reduction is needed.
Q: How does Melanotan-1 compare to natural tanning for photoprotection? A: Melanotan-1 produces eumelanin (the photoprotective form) without requiring UV-induced DNA damage to trigger melanogenesis. Natural tanning requires cumulative UV exposure to stimulate melanin production, meaning DNA damage precedes protection. Clinical trials in erythropoietic protoporphyria patients showed 75% reduction in phototoxic reactions with Melanotan-1 pre-treatment versus natural tanning protocols.
Q: Can Melanotan-1 be used by individuals with a history of melanoma? A: Melanotan-1 use in individuals with personal or family history of melanoma is contraindicated without explicit physician oversight. MC1R activation upregulates melanocyte proliferation. Which is the mechanism of both photoprotection and, theoretically, melanoma progression in individuals with existing dysplastic lesions. No clinical data currently supports safety in this population.
Q: What is the difference between Melanotan-1 and Melanotan-2? A: Melanotan-1 (afamelanotide) is a linear 13-amino-acid peptide that selectively binds MC1R with minimal activity at MC3R and MC4R. Producing melanogenesis with few systemic effects. Melanotan-2 is a cyclic 7-amino-acid analog with broader receptor activity (MC1R, MC3R, MC4R), causing melanogenesis plus appetite suppression, increased libido, and spontaneous erections at higher frequency. Melanotan-1 is FDA-approved (as Scenesse implants); Melanotan-2 is not.
Q: How should I store reconstituted Melanotan-1? A: Store reconstituted Melanotan-1 at 2–8°C (refrigerated) in the original amber vial to protect from light degradation. Do not freeze. Freezing causes ice crystal formation that denatures the peptide structure. Reconstituted peptide remains stable for 28 days under proper refrigeration. After 28 days, potency declines due to hydrolytic cleavage of peptide bonds.
Q: Can I travel with Melanotan-1 during the loading phase? A: Yes, but temperature control is critical. Unreconstituted lyophilized Melanotan-1 tolerates ambient temperature (up to 25°C) for 48–72 hours without significant degradation. Reconstituted peptide must remain refrigerated. Use a portable medication cooler (FRIO wallets use evaporative cooling and maintain 2–8°C for 36–48 hours without ice). If refrigeration is unavailable during travel, postpone the loading phase until stable storage is available.
Q: What happens if I miss a dose during the maintenance phase? A: Missing a single maintenance dose (within 3–4 days of the scheduled injection) does not cause noticeable pigmentation loss. Resume your regular twice-weekly schedule at the next dose. Do not double-dose to 'make up' for the missed injection. Missing multiple consecutive doses (7+ days) will cause gradual fading; if this occurs, return to modified loading (0.25mg daily for 5–7 days) to restore baseline pigmentation.
Q: Is Melanotan-1 legal for personal use? A: Melanotan-1 (afamelanotide) is FDA-approved only as Scenesse implants for erythropoietic protoporphyria under physician administration. Compounded Melanotan-1 for personal use exists in a regulatory grey area. It is not explicitly scheduled or banned, but it is not approved for cosmetic photoprotection. Sourcing from research peptide suppliers or compounding pharmacies is legal in most jurisdictions, but the user assumes responsibility for off-label use and injection safety.
Q: Can I combine Melanotan-1 with other peptides or medications? A: No known major drug interactions exist between Melanotan-1 and common medications (NSAIDs, statins, antihypertensives). However, combining Melanotan-1 with other peptides that affect melanocyte signaling (e.g., alpha-MSH analogs) is not recommended without physician oversight. Concurrent use of photosensitizing medications (tetracyclines, thiazides, NSAIDs) increases UV sensitivity and may require dose adjustments to the UVB exposure schedule.
Q: How long does photoprotection last after stopping Melanotan-1? A: Melanin density begins declining 2–3 weeks after the final maintenance dose as melanin degradation outpaces synthesis. Pigmentation fades to near-baseline levels within 8–12 weeks without continued dosing or UVB exposure. Periodic UVB exposure (once every 10–14 days) slows this fade but does not prevent it entirely. To maintain photoprotection long-term, maintenance dosing must continue indefinitely.
All compounds discussed on this page are sold for research use only and are not for human consumption.
References
Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.
- Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
- Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
- A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
- Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
- Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
- Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
- Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA